Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | FNTA | P49354 | 2/20 | 0.50 |
| ▸ | FNTB | P49356 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151524 | 0.89 | ALDH1A1 (0.61) | NR4A1SRD5A2TSHRALDH1A1ALOX15 | |
| SCHEMBL1819616 | 0.88 | NR4A1 (0.69) | NR4A1SRD5A2TSHRALDH1A1ALOX15 | |
| SCHEMBL21835148 | 0.86 | ALDH1A1 (0.53) | NR4A1SRD5A2TSHRALDH1A1ALOX15 | |
| SCHEMBL11850279 | 0.85 | SRD5A2 (0.56) | NR4A1SRD5A2TSHRALDH1A1ALOX15 | |
| SCHEMBL1821327 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALDH1A1FNTA | |
| SCHEMBL29583954 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALDH1A1FNTA | |
| SCHEMBL4801729 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALDH1A1FNTA | |
| SCHEMBL1246659 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALDH1A1FNTA | |
| SCHEMBL4551433 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALDH1A1FNTA | |
| SCHEMBL275485 | 0.81 | TSHR (0.65) | NR4A1TSHRALDH1A1ALOX15PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9358222-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-07 | — | — | US | disclosed |
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | disclosed |
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | disclosed |
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | disclosed |
| US-8618158-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| EP-2315749-A2 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009156735-A2 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| US-4058529-A | Polycyclic amino derivatives of pyrrolidone and piperidone | CIBA-GEIGY CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194486-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885 |
| US-20110224274-A1 | New Therapeutic Agents | TP53, MDM2, TP53BP1 | NR4A1 2295/4885SRD5A2 3329/4885TSHR 1980/4885 |
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885 |
| US-20160355478-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.